The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma

Radiotherapy and Oncology

Volumn 117, Issue 1, 2015, Pages 91-98

  Lyhne, Nina M ^a   Primdahl, Hanne ^a   Kristensen, Claus A ^b   Andersen, Elo ^c   Johansen, Jørgen ^d   Andersen, Lisbeth J ^e   Evensen, Jan ^f   Mortensen, Hanna R ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Accelerated radiotherapy; Glottic cancer; Head and neck squamous cell carcinoma

Indexed keywords

ACCELERATION; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLOTTIC SQUAMOUS CELL CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LARYNGECTOMY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; ACUTE DISEASE; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPARATIVE STUDY; GLOTTIS; HEAD AND NECK NEOPLASMS; INCIDENCE; KAPLAN MEIER METHOD; LARYNGEAL NEOPLASMS; MIDDLE AGED; MUCOSITIS; PHASE 3 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RADIATION INJURIES; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; FEMALE; GLOTTIS; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MUCOSITIS; RADIATION INJURIES; RADIOTHERAPY;

EID: 84946481844     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.07.004     Document Type: Article

References (36)

1. H.R. Withers, J.M. Taylor, and B. Maciejewski The hazard of accelerated tumor clonogen repopulation during radiotherapy Acta Oncol 27 1988 131 146
2. O. Hansen, J. Overgaard, H.S. Hansen, M. Overgaard, M. Hoyer, K.E. Jorgensen, and et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation Radiother Oncol 43 1997 47 51
3. J. Overgaard, H.S. Hansen, L. Specht, M. Overgaard, C. Grau, E. Andersen, and et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial Lancet 362 2003 933 940
4. P. Lassen, J.G. Eriksen, A. Krogdahl, M.H. Therkildsen, B.P. Ulhoi, M. Overgaard, and et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial Radiother Oncol 100 2011 49 55
5. J.G. Eriksen, T. Steiniche, and J. Overgaard (DAHANCA) DH and NC study group. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study Radiother Oncol 74 2005 93 100
6. H.R. Mortensen, J. Overgaard, L. Specht, M. Overgaard, J. Johansen, J.F. Evensen, and et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer Radiother Oncol 103 2012 69 75
7. H.R. Mortensen, J. Overgaard, K. Jensen, L. Specht, M. Overgaard, J. Johansen, and et al. Factors associated with acute and late dysphagia in the DAHANCA 6 and 7 randomized trial with accelerated radiotherapy for head and neck cancer Acta Oncol 52 2013 1535 1542
8. B. Zackrisson, P. Nilsson, E. Kjellen, K.A. Johansson, H. Modig, E. Brun, and et al. Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma-the ARTSCAN study Radiother Oncol 100 2011 41 48
9. S.M. Jackson, L.M. Weir, J.H. Hay, V.H. Tsang, and J.S. Durham A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer Radiother Oncol 43 1997 39 46
10. P. Olmi, S. Crispino, C. Fallai, V. Torri, F. Rossi, A. Bolner, and et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy - A multicenter randomized trial Int J Radiat Oncol Biol Phys 55 2003 78 92
11. Zackrisson B, Kjellén Elisabeth, Söderström K, Brun E, Nyman J NP. Five-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - the ARTSCAN trial. Radiother Oncol 2015; Accepted for publication.
12. A. Hliniak, B. Gwiazdowska, Z. Szutkowski, E. Kraszewska, P. Kukolowicz, A. Jarzabski, and et al. A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time Radiother Oncol 62 2002 1 10
13. J.C. Horiot, P. Bontemps, W. van den Bogaert, R. Le Fur, D. van den Weijngaert, M. Bolla, and et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial Radiother Oncol 44 1997 111 121
14. J.J. Beitler, Q. Zhang, K.K. Fu, A. Trotti, S.A. Spencer, C.U. Jones, and et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer Int J Radiat Oncol Biol Phys 89 2014 13 20
15. K. Skladowski, B. Maciejewski, M. Golen, B. Pilecki, W. Przeorek, and R. Tarnawski Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity Radiother Oncol 55 2000 101 110
16. J. Bourhis, J. Overgaard, H. Audry, K.K. Ang, M. Saunders, J. Bernier, and et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Lancet 368 2006 843 854
17. A. Al-Mamgani, P.H. van Rooij, D.P. Woutersen, R. Mehilal, L. Tans, D. Monserez, and et al. Radiotherapy for T1-2N0 glottic cancer: a multivariate analysis of predictive factors for the long-term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients Clin Otolaryngol 38 2013 306 312
18. H. Yamazaki, K. Nishiyama, E. Tanaka, M. Koizumi, and M. Chatani Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time Int J Radiat Oncol Biol Phys 64 2006 77 82
19. S.H. Moon, K.H. Cho, E.J. Chung, C.G. Lee, K.C. Lee, G.Y. Chai, and et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study Radiother Oncol 110 2014 98 103
20. A. Trotti, Q. Zhang, S.M. Bentzen, B. Emami, M.E. Hammond, C.U. Jones, and et al. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512) Int J Radiat Oncol Biol Phys 89 2014 958 963
21. J. Overgaard, J. Alsner, J. Eriksen, M.R. Horsman, and C. Grau Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck Rays 25 2000 313 319
22. S. Dische, M. Saunders, A. Barrett, A. Harvey, D. Gibson, and M. Parmar A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer Radiother Oncol 44 1997 123 136
23. J. Overgaard, M. Hjelm-Hansen, L.V. Johansen, and A.P. Andersen Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx Acta Oncol 27 1988 147 152
24. P. Blanchard, B. Baujat, V. Holostenco, A. Bourredjem, C. Baey, J. Bourhis, and et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site Radiother Oncol 100 2011 33 40
25. J. Bentzen, K. Toustrup, J.G. Eriksen, H. Primdahl, L.J. Andersen, and J. Overgaard Locally advanced Head and Neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study Acta Oncol 54 2015 1001 1007
26. J. Overgaard, H.S. Hansen, M. Overgaard, L. Bastholt, A. Berthelsen, L. Specht, and et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother Oncol 46 1998 135 146
27. J. Overgaard, H.S. Hansen, A.P. Andersen, M. Hjelm-Hansen, K. Jorgensen, E. Sandberg, and et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study Int J Radiat Oncol Biol Phys 16 1989 1065 1068
28. TD of VALCS Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer N Engl J Med 324 1991 1685 1690
29. P.A. Groome, B. O'Sullivan, J.C. Irish, D.M. Rothwell, K.S. Math, R.J. Bissett, and et al. Glottic cancer in Ontario, Canada and the SEER areas of the United States. Do different management philosophies produce different outcome profiles? J Clin Epidemiol 54 2001 301 315
30. C.R. Boje, S.O. Dalton, T.K. Gronborg, H. Primdahl, C.A. Kristensen, E. Andersen, and et al. The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database Acta Oncol 52 2013 285 293
31. J. Jakobsen, O. Hansen, K.E. Jorgensen, and L. Bastholt Lymph node metastases from laryngeal and pharyngeal carcinomas-calculation of burden of metastasis and its impact on prognosis Acta Oncol 37 1998 489 493
32. L.V. Johansen, C. Grau, and J. Overgaard Glottic carcinoma-patterns of failure and salvage treatment after curative radiotherapy in 861 consecutive patients Radiother Oncol 63 2002 257 267
33. C.M. Hoff Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy Acta Oncol 51 2012 419 432
34. J. Overgaard, B.K. Mohanti, N. Begum, R. Ali, J.P. Agarwal, M. Kuddu, and et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial Lancet Oncol 11 2010 553 560
35. A. Trotti, and M. Machtay RTOG 9003: Legacies of a Landmark Trial Int J Radiat Oncol 90 2014 253 254
36. D.I. Rosenthal, C.D. Fuller, L.J. Peters, and H.D. Thames Final Report of Radiation Therapy Oncology Group Protocol 9003: provocative, but limited conclusions from exploratory analyses Int J Radiat Oncol 92 2015 715 717